respiratori
viral
infect
infant
young
children
frequent
caus
ill
easili
progress
hospit
death
current
licens
vaccin
prevent
respiratori
viral
diseas
children
younger
month
reflect
safeti
concern
difficulti
induc
effect
immun
respons
infant
review
discuss
vaccin
develop
current
develop
influenza
respiratori
syncyti
viru
focu
studi
perform
demonstr
safeti
efficaci
impact
immunolog
immatur
matern
antibodi
infant
respons
vaccin
publish
elsevi
ltd
acut
lower
respiratori
infect
common
caus
infant
mortal
worldwid
respiratori
syncyti
viru
rsv
frequent
infect
agent
respons
infant
hospit
although
virus
influenza
parainfluenzavirus
type
human
metapneumoviru
adenoviru
coronaviru
rhinovirus
also
respons
upper
lower
respiratori
tract
ill
death
addit
new
virus
human
bocaviru
polyomavirus
recogn
caus
respiratori
diseas
infant
young
children
current
vaccin
protect
children
pathogen
licens
influenza
vaccin
avail
children
month
age
progress
made
develop
vaccin
protect
young
rsv
review
discuss
factor
need
consid
develop
safe
effect
vaccin
influenza
rsv
infant
incid
rsv
influenza
infect
young
children
vari
substanti
year
year
mortal
due
infect
occur
predominantli
develop
world
infant
infect
respiratori
virus
like
sever
diseas
older
children
larg
viru
replic
control
immatur
immun
system
destruct
lung
epitheli
cell
inflammatori
respons
like
signific
impact
fine
architectur
function
infant
lung
seropreval
studi
indic
children
experienc
least
one
influenza
infect
year
age
whilst
virtual
infect
rsv
prior
second
third
birthday
respiratori
viru
infect
acut
ill
resolv
without
complic
estim
children
younger
year
die
worldwid
result
influenzaassoci
acut
lower
respiratori
viru
infect
alri
mortal
similarli
high
rsvassoci
alri
approxim
death
worldwid
estim
year
children
age
group
hospit
rate
rsv
influenza
viru
infect
highest
among
infant
less
one
year
age
unit
state
us
rsv
infect
account
hospit
per
year
among
children
year
age
peak
age
month
mani
million
clinic
visit
hospit
rate
infant
us
influenza
viru
infect
estim
order
per
year
infant
month
age
clinic
visit
approxim
higher
addit
burden
diseas
caus
infect
infanc
children
also
serv
import
vector
transmit
virus
adult
elderli
may
vulner
infect
due
absenc
immun
drift
influenza
strain
due
wane
immun
rsv
suscept
associ
complic
increas
underli
medic
condit
vaccin
target
prevent
influenza
rsv
diseas
infant
would
benefit
public
health
provid
individu
protect
improv
herd
immun
rsv
influenza
viru
envelop
negativesens
singlestrand
rna
virus
belong
paramyxovirida
orthomyxovirida
famili
respect
rsv
singl
serotyp
two
main
antigen
subtyp
b
three
type
influenza
virus
infect
human
b
c
type
virus
subdivid
subtyp
base
antigen
profil
two
envelop
glycoprotein
hemagglutinin
ha
neuraminidas
na
subtyp
may
character
genotyp
clade
base
sequenc
obtain
envelop
gene
two
distinct
lineag
also
identifi
influenza
b
virus
base
result
antigen
profil
obtain
mainli
crosshemagglutin
test
us
inactiv
split
trival
influenza
vaccin
licens
children
month
old
live
attenu
vaccin
use
healthi
children
year
old
trival
inactiv
influenza
vaccin
tiv
contain
mixtur
three
virus
repres
circul
influenza
subtyp
strain
singl
b
strain
quadrival
inactiv
vaccin
contain
influenza
subtyp
well
byamagata
bvictoria
lineag
undergo
clinic
develop
quadrival
formul
live
attenu
influenza
laiv
vaccin
recent
approv
us
monoval
vaccin
also
exist
prevent
infect
due
pandem
pdm
influenza
strain
influenza
immun
recommend
individu
older
month
us
allow
time
product
protect
antibodi
level
vaccin
occur
influenza
begin
circul
commun
children
age
month
year
vaccin
influenza
first
time
recommend
regimen
includ
dose
administ
week
apart
annual
vaccin
recommend
vaccin
usual
reformul
includ
new
viru
strain
small
chang
ha
na
surfac
glycoprotein
allow
escap
preexist
immun
antigen
drift
annual
dose
also
provid
boost
preexist
immun
antigen
strain
chang
e
need
sinc
antibodi
titer
often
decreas
level
associ
protect
month
epidem
contrast
vaccin
current
licens
prevent
rsv
diseas
childhood
spite
multipl
attempt
persist
effort
initi
vaccin
test
alumprecipit
formalininactiv
fi
wholeviru
vaccin
develop
infant
immun
seri
administ
month
age
subsequ
develop
rsvspecif
serum
antibodi
respons
poor
vitro
neutral
activ
howev
respons
protect
follow
subsequ
exposur
rsv
similar
rate
infect
vaccine
control
children
given
formalininactiv
vaccin
hospit
sever
rsv
lower
respiratori
tract
infect
compar
control
receiv
similarli
prepar
parainfluenza
viru
type
vaccin
two
rsvvaccin
children
die
unfortun
legaci
formalininactiv
rsv
vaccin
haunt
effort
develop
rsv
vaccin
ever
sinc
led
much
research
investig
understand
caus
enhanc
postvaccin
rsv
diseas
infant
singl
unifi
hypothesi
entir
explain
disast
although
sever
line
investig
provid
import
clue
factor
may
contribut
enhanc
diseas
descript
factor
beyond
scope
present
report
howev
detail
review
recent
includ
skew
immun
respons
favor
cytokin
allerg
respons
upon
exposur
viru
ii
dysregul
cytokin
respons
heighten
respons
upon
exposur
rsv
result
cytokin
storm
iii
failur
induc
adequ
neutral
antibodi
respons
due
modif
critic
epitop
fusion
f
glycoprotein
follow
formaldehyd
inactiv
iv
low
antibodi
avid
follow
immun
firsv
vaccin
increas
tissu
damag
small
airway
due
deposit
complement
cell
decor
antirsvigg
immun
complex
v
modul
type
interferon
respons
result
bind
rsv
fusion
glycoprotein
rsvf
toll
like
receptor
vi
contribut
host
factor
enhanc
suscept
sever
diseas
genet
polymorph
detect
higher
frequenc
among
infant
sever
rsv
infect
diseas
compar
control
mild
diseas
mani
line
evid
demonstr
import
role
neutral
antibodi
elicit
respons
two
rsv
envelop
glycoprotein
includ
fusion
protein
rsvf
attach
protein
rsvg
provid
long
term
protect
infect
random
doubleblind
placebocontrol
clinic
trial
monthli
infus
polyclon
human
immunoglobulin
respigam
contain
high
titer
rsv
neutral
antibodi
yield
postinfus
trough
level
excess
decreas
rsv
hospit
highrisk
infant
compar
infant
given
iggfre
albumin
control
likewis
monthli
inject
antirsvf
human
monoclon
antibodi
palivizumab
neutral
fusioninhibit
activ
also
significantli
decreas
incid
hospit
due
rsv
lower
respiratori
tract
diseas
among
highrisk
infant
studi
provid
proof
efficaci
passivelyadminist
neutral
antirsv
antibodi
also
provid
support
matern
immun
program
seek
elicit
high
titer
rsv
neutral
antibodi
third
trimest
transfer
across
placenta
provid
newborn
protect
least
first
month
life
studi
also
suggest
rsv
vaccin
capabl
elicit
neutral
antibodi
respons
particularli
direct
rsvf
protein
potenti
succeed
although
rsv
vaccin
current
licens
varieti
experiment
vaccin
develop
mani
undergo
test
clinic
includ
coldadapt
liveattenu
virus
recombinantchimer
murin
bovinehuman
strain
vector
vaccin
includ
replic
incompet
recombin
adenoviru
alphaviru
vaccin
variou
vectorexpress
viruslikeparticl
contain
rsv
protein
bcg
recombin
express
rsvf
subunit
rsvf
vaccin
review
schmidt
licensur
vaccin
prevent
influenza
rsv
diseas
infant
base
demonstr
safeti
efficaci
wellcontrol
clinic
trial
target
popul
typic
evalu
includ
preclin
test
phase
phase
phase
clinic
studi
sometim
addit
postmarket
studi
also
known
phase
requir
subsequ
licensur
preclin
studi
may
includ
proofofconcept
studi
anim
demonstr
immunogen
evid
efficaci
follow
live
viru
challeng
influenza
rsv
vaccin
studi
typic
perform
small
anim
mice
cotton
rat
andor
ferret
see
tabl
summari
rsv
vaccin
anim
ideal
challeng
virus
repres
subtyp
b
virus
sinc
expect
effect
vaccin
need
provid
immun
subtyp
need
adjuv
enhanc
modifi
immun
respons
also
justifi
use
preclin
test
repeatdos
toxicolog
studi
rat
rabbit
may
need
well
reproduct
toxicolog
studi
vaccin
intend
use
matern
immun
program
preclin
test
influenza
rsv
vaccin
anim
model
also
includ
studi
demonstr
attenu
phenotyp
stabil
live
viru
vaccin
nonrepl
rsv
vaccin
addit
test
anim
requir
order
provid
evid
vaccin
unlik
prime
enhanc
suscept
vaccin
subsequ
expos
wildtyp
rsv
infect
postvaccin
safeti
studi
evalu
vaccin
prime
enhanc
diseas
necessari
test
may
proceed
children
gener
need
prior
test
candid
vaccin
rsvseroposit
individu
irrespect
vaccin
type
phase
test
vaccin
target
use
infant
popul
gener
proce
use
doserang
stepdown
design
character
evalu
candid
small
number
n
healthi
adult
follow
doserang
test
small
group
progress
younger
seroposit
children
prior
proceed
doserang
studi
progress
younger
seroneg
infant
serostatu
youngest
infant
exampl
less
month
age
typic
complic
presenc
matern
antibodi
usual
rang
dose
test
within
age
cohort
begin
lowest
proceed
increment
test
use
higher
dose
vaccin
safe
dose
identifi
target
popul
phase
test
small
number
children
may
use
optim
number
dose
requir
achiev
maximum
vaccin
take
point
clinic
studi
enter
phase
vaccin
immun
schedul
test
larger
number
children
n
subject
order
accru
addit
safeti
data
evid
effect
live
viru
vaccin
transmiss
studi
may
conduct
assess
abil
vaccin
viru
spread
infect
contact
reliabl
clinic
tool
use
demonstr
efficaci
pivot
trial
includ
diari
questionnair
case
definit
score
method
assess
diseas
sever
critic
laboratori
test
assay
assess
immunogen
identifi
infect
individu
proven
phase
one
retrospect
look
data
acquir
year
clinic
trial
involv
variou
rsv
candid
vaccin
strain
show
rate
rsvassoci
lower
respiratori
tract
ill
lri
similarli
low
vaccine
control
winter
subsequ
vaccin
administr
includ
data
approxim
children
given
liveattenu
vaccin
month
age
span
age
group
highest
risk
enhanc
diseas
none
children
involv
studi
hospit
rsv
ill
winter
season
follow
immun
find
suggest
liveattenu
virus
administ
intranas
rout
unlik
prime
enhanc
diseas
nevertheless
part
safeti
assess
vaccin
infant
enrol
phase
vaccin
trial
typic
follow
one
two
rsv
season
vaccin
administr
detect
signal
might
indic
enhanc
suscept
sever
diseas
phase
clinic
trial
provid
proof
vaccin
efficaci
thorough
look
safeti
new
vaccin
predecessor
proof
efficaci
obtain
larg
multicent
random
placebocontrol
doubleblind
clinic
trial
show
attack
rate
ie
cultureconfirm
infect
andor
diseas
endpoint
hospit
significantli
reduc
among
vaccine
compar
incid
attack
rate
unvaccin
popul
clinic
investig
estim
children
birth
month
age
would
need
per
arm
power
detect
vaccin
efficaci
prevent
cultureconfirm
symptomat
respiratori
tract
infect
due
rsv
altern
vaccin
alreadi
licens
case
season
inactiv
influenza
vaccin
noninferior
trial
may
use
compar
immunogen
new
vs
licens
product
use
surrog
serolog
marker
efficaci
hemagglutin
inhibit
hi
antibodi
titer
scenario
lower
bound
confid
interv
serorespons
rate
vaccin
compar
geometr
mean
titer
concentr
antibodi
also
compar
group
show
valu
vari
case
phase
trial
demonstr
new
vaccin
achiev
minimum
respons
rate
minimum
protect
titer
among
major
vaccine
howev
sinc
immun
correl
protect
infant
given
influenza
vaccin
controversi
may
vari
vaccin
type
clinic
efficaci
studi
may
still
requir
sinc
mani
vaccin
administ
children
phase
studi
design
assess
safeti
immunogen
candid
vaccin
given
concomitantli
routin
recommend
vaccin
use
noninferior
design
phase
studi
also
extend
safeti
databas
target
popul
test
vaccin
larg
number
subject
eg
evalu
live
viru
vaccin
major
popul
use
safeti
databas
need
order
reliabl
assess
reactogen
vaccin
strain
prelicensur
vaccin
studi
conduct
healthi
popul
use
vaccin
special
popul
asthma
hiv
infect
use
biolog
respons
modifi
may
requir
separ
studi
depend
vaccin
type
order
obtain
approv
use
individu
condit
licensur
postmarket
phase
studi
use
obtain
complet
assess
effect
decreas
ill
vaccin
use
gener
popul
sometim
obtain
addit
safeti
data
rare
advers
event
vaccin
given
larger
number
would
case
recommend
univers
use
us
birth
cohort
million
children
per
year
us
fda
monitor
safeti
new
vaccin
children
use
postlicensur
rapid
immun
safeti
monitor
prism
program
cdc
perform
rapid
cycl
analysi
detect
safeti
signal
realtim
center
particip
vaccin
safeti
datalink
program
supplement
passiv
report
accru
vaccin
advers
event
report
system
vaer
also
monitor
continu
potenti
signal
seriou
advers
event
outlin
path
licensur
vaccin
design
newborn
young
infant
care
scrutin
assur
expos
vaccin
like
deriv
benefit
minim
risk
toward
end
vaccin
prevent
influenza
respiratori
syncyti
viru
diseas
assess
local
system
toxic
gener
liveattenu
respiratori
viru
vaccin
typic
given
intranas
caus
lower
respiratori
tract
ill
bronchiol
pneumonia
wheez
signific
increas
fever
upper
respiratori
infect
uri
symptom
cough
nasal
congest
acut
otiti
media
particularli
import
infant
month
age
sinc
oblig
nose
breather
may
toler
nasal
stuffi
small
amount
rhinorrhea
nasal
congest
might
accept
older
children
level
interfer
nurs
feed
sleep
infant
like
accept
common
advers
event
seen
administr
live
attenu
influenza
vaccin
laiv
runni
nose
nasal
congest
incid
seriou
advers
reaction
low
episod
wheez
increas
laivvaccin
children
less
year
age
among
age
histori
recurr
episod
wheez
asthma
result
lower
age
limit
live
attenu
influenza
viru
vaccin
set
month
age
vaccin
recommend
use
asthma
predispos
wheez
small
studi
assess
safeti
trival
inactiv
influenza
viru
vaccin
tiv
vaccin
infant
month
age
englund
et
al
enrol
substanti
number
infant
week
age
n
given
tiv
given
placebo
studi
assess
safeti
immunogen
tiv
age
group
trial
detect
signific
differ
rate
fever
seriou
advers
event
group
sever
advers
event
febril
seizur
narcolepsi
associ
influenza
vaccin
administ
young
children
highlight
need
care
studi
identifi
root
caus
event
safeti
well
futur
formul
ensur
sinc
number
pathogen
result
similar
respiratori
symptom
efficaci
respiratori
viru
vaccin
test
use
combin
clinic
virolog
endpoint
primari
efficaci
endpoint
pediatr
phase
studi
inactiv
live
influenza
vaccin
diseas
sign
fever
addit
upper
lower
respiratori
tract
symptom
accompani
confirm
influenza
viru
infect
use
nasal
wash
throat
swab
identifi
pathogen
associ
respiratori
ill
infect
rsv
influenza
viru
usual
confirm
cultur
sampl
suscept
cell
amplif
viral
gene
pcr
provid
addit
inform
infect
pathogen
becom
suitabl
altern
test
method
measur
vaccin
immunogen
replac
clinic
studi
establish
efficaci
immun
mechan
contribut
protect
complet
understood
differ
arm
immun
system
play
role
prevent
infect
expedit
clearanc
infect
cell
addit
specif
immun
endpoint
use
surrog
marker
protect
adult
alway
appli
young
children
exampl
hemagglutin
inhibit
hi
titer
follow
inactiv
influenza
vaccin
often
use
correl
protect
influenza
diseas
adult
howev
recent
clinic
studi
adjuv
inactiv
influenza
vaccin
show
higher
hi
titer
similar
rate
protect
may
requir
protect
children
younger
year
age
even
higher
titer
requir
achiev
greater
degre
protect
anoth
difficulti
infer
potenti
efficaci
vaccin
serolog
respons
differ
protect
immun
mechan
induc
differ
vaccin
type
antiha
antibodi
contribut
efficaci
inactiv
influenza
vaccin
protect
induc
live
attenu
influenza
vaccin
young
children
associ
induct
ifngproduc
cell
may
also
reli
nainhibit
antibodi
virusspecif
mucos
iga
demonstr
adult
shown
live
attenu
influenza
vaccin
like
rsv
vaccin
similarli
induc
cellular
cell
well
mucos
siga
serum
igg
neutral
antibodi
respons
provid
greatest
chanc
protect
infect
difficult
induc
either
b
cell
respons
infant
due
immatur
immun
system
absenc
preexist
memori
b
cell
review
ref
factor
contribut
ineffect
immun
respons
infant
includ
defect
innat
adapt
mechan
addit
presenc
matern
antibodi
adapt
immun
respons
control
regulatori
cell
treg
increas
newborn
cell
clearli
import
utero
protect
gener
respons
matern
antigen
howev
treg
suppress
cellmedi
respons
first
week
life
possibl
decreas
stimulatori
capac
antigenpres
cell
apc
result
reduc
number
activ
cell
result
fewer
antigenspecif
cell
environ
also
produc
qualit
differ
neonat
milieu
preferenti
support
develop
cell
simultan
elimin
cell
induc
apoptosi
addit
quantit
qualit
defici
antigenspecif
cell
respons
b
cell
respons
reduc
infant
due
limit
b
cell
repertoir
lack
previou
exposur
foreign
antigen
consequ
high
avid
antibodi
usual
stimul
initi
exposur
vaccin
antigen
pathogen
young
gener
effect
respons
infant
must
also
overcom
presenc
matern
antibodi
mask
neutral
antibodi
epitop
epitop
block
infant
may
attribut
either
pathogenspecif
igg
transfer
utero
matern
iga
obtain
breastmilk
data
suggest
balanc
quantiti
matern
antibodi
target
antigen
predict
success
respons
inactiv
vaccin
interfer
matern
antibodi
result
suboptim
respons
influenza
vaccin
administ
parenter
anim
human
theori
mucos
vaccin
potenti
overcom
obstacl
sinc
vaccin
immunogen
mucos
surfac
less
like
hinder
passiv
acquir
serum
antibodi
ensur
uniform
adequ
protect
newborn
respiratori
virus
includ
infect
due
influenza
respiratori
syncyti
viru
matern
immun
propos
random
control
studi
show
immun
trimest
pregnanc
trival
inactiv
influenza
vaccin
reduc
influenza
ill
infant
born
vaccin
mother
significantli
reduc
overal
incid
febril
respiratori
ill
newborn
mother
support
use
strategi
protect
infant
diseas
success
vaccin
approach
may
import
face
influenza
pandem
shift
ha
na
antigen
matern
antibodi
specif
season
influenza
strain
like
ineffect
protect
either
mother
child
antibodi
detect
pandem
viru
vaccin
mother
offspr
demonstr
transplacent
transfer
antibodi
effici
achiev
protect
level
persist
least
week
major
infant
respiratori
ill
children
younger
month
predominantli
due
rsv
reflect
need
high
titer
transplacentallytransf
neutral
antibodi
rsv
diseas
reduc
level
matern
neutral
antibodi
present
highrisk
infant
receiv
monthli
infus
rsvspecif
hyperimmunoglobulin
maintain
level
serum
neutral
antibodi
excess
matern
immun
prevent
rsv
infect
infanc
therefor
reason
approach
protect
young
infant
pathogen
one
studi
explor
possibl
use
investig
purifi
rsvf
vaccin
titer
boost
suffici
baselin
improv
protect
infant
born
vaccin
mother
robust
antibodi
respons
transfer
newborn
use
approach
like
immun
would
provid
infant
first
month
life
howev
pitfal
associ
passiv
immun
matern
antibodi
still
present
time
infant
vaccin
may
reduc
immunogen
vaccin
result
less
effect
respons
due
induct
nonneutr
antibodi
studi
infant
suggest
case
measl
therefor
care
consider
given
recommend
appropri
age
measl
vaccin
anim
studi
suggest
immun
presenc
matern
antibodi
detriment
outcom
vaccin
efficaci
prevent
vaccin
take
may
even
harm
instanc
piglet
vaccin
influenza
presenc
homolog
matern
deriv
antibodi
exhibit
exacerb
diseas
prolong
clinic
sign
subsequ
challeng
live
viru
howev
enhanc
diseas
avoid
weanl
immun
liveattenu
vaccin
suggest
earli
intranas
vaccin
infant
live
attenu
rsv
influenza
viru
vaccin
like
safe
immunogen
even
matern
antibodi
present
ration
design
influenza
rsv
vaccin
safe
immunogen
young
infant
overcom
hurdl
immun
immatur
matern
antibodi
live
attenu
vaccin
administ
via
mucos
rout
offer
one
approach
surmount
interfer
matern
antibodi
avoid
potenti
diseas
exacerb
induc
inactiv
vaccin
administ
parenter
rout
addit
live
viru
stimul
balanc
helper
cell
respons
least
theori
less
like
produc
predomin
cytokin
environ
often
associ
exacerb
diseas
mucos
vaccin
respiratori
viru
addit
advantag
particularli
young
children
local
immun
respons
induc
includ
secret
virusspecif
iga
antibodi
may
necessari
protect
consequ
vaccin
efficaci
may
excel
even
virusspecif
igg
respons
serum
robust
demonstr
live
attenu
influenza
vaccin
young
children
sinc
rsv
infect
sever
outcom
newborn
need
develop
effect
vaccin
protect
infant
birth
month
clinic
trial
live
rsv
vaccin
therefor
aim
identifi
vaccin
viru
suitabl
attenu
yet
still
immunogen
age
group
develop
vaccin
candid
greatli
improv
due
use
sequenc
analysi
identifi
attenu
mutat
genet
engin
construct
new
virus
use
nonhuman
primat
preclin
anim
model
rule
viru
construct
insuffici
overli
attenu
clinic
trial
vaccin
candid
shown
safe
immunogen
month
old
infant
identifi
revers
attenu
sequenc
virus
shed
vaccine
longer
temperatur
sensit
recent
studi
suggest
revers
decreas
stabil
codon
associ
attenu
mutat
provid
confid
modifi
viru
may
prove
suitabl
vaccin
seed
immunogen
consequ
effect
influenza
rsv
vaccin
develop
could
potenti
improv
inclus
adjuv
sinc
reinfect
rsv
common
throughout
childhood
expect
success
vaccin
may
need
elicit
immun
respons
exceed
seen
follow
natur
infect
depend
adjuv
increas
immunogen
may
result
improv
antigen
uptak
antigenpres
cell
activ
innat
respons
support
induct
respons
creat
environ
germin
center
allow
greater
prolifer
antigenspecif
b
cell
larg
number
cell
driven
becom
memori
cell
exampl
adjuv
propos
improv
neonat
respons
coadminist
inactiv
influenza
vaccin
support
develop
respons
newborn
mice
increas
protect
mice
challeng
viru
adult
adjuv
activ
sever
altern
formul
demonstr
pediatr
clinic
trial
includ
squalenebas
adjuv
discuss
earlier
benefit
ad
vaccin
compon
safeti
need
demonstr
clinic
test
immun
young
children
monoval
inactiv
vaccin
contain
squalenebas
adjuv
atocopherol
vitamin
e
discontinu
due
observ
increas
incid
narcolepsi
scandinavia
interestingli
narcolepsi
also
describ
follow
infect
viru
therefor
clear
whether
unusu
advers
event
due
adjuv
compon
whether
similar
increas
would
occur
popul
expos
unadjuv
vaccin
find
like
point
import
surveil
program
identifi
evalu
advers
event
realtim
order
respond
signal
quickli
make
modifi
recommend
vaccin
use
critic
need
vaccin
respiratori
virus
includ
rsv
influenza
infant
month
age
immatur
immun
system
presenc
matern
antibodi
may
prevent
induct
robust
neutral
antibodi
respons
vaccin
infant
live
attenu
viru
vaccin
administ
intranas
provid
potenti
mean
overcom
obstacl
extrem
difficult
identifi
suitabl
attenu
viru
strain
retain
immunogen
nonrepl
vaccin
run
risk
prime
enhanc
wildtyp
diseas
need
evalu
care
test
youngest
infant
natur
predispos
respons
evalu
programmat
effort
consid
matern
immun
togeth
pediatr
vaccin
need
approach
may
provid
neonat
infant
suffici
immun
safe
success
immun
